Optimi Health Completes First Psilocybin Export to UK for Phase 2 Trial
Optimi Health Corp. has exported naturally derived psilocybin to the UK for a planned Phase 2 clinical trial, marking a milestone in international psychedelic drug distribution.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has completed its first export of naturally derived psilocybin to the United Kingdom, supporting a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules, manufactured at the company's GMP facility in Princeton, British Columbia.
The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, according to Optimi Health. The export was authorized by Health Canada and the UK Home Office, underscoring the growing regulatory acceptance of psychedelic-assisted therapies. The company noted that the products were cultivated, extracted, and manufactured in-house under its Drug Establishment Licence, reinforcing its position as a vertically integrated GMP supplier supporting both regulated patient access programs and clinical research initiatives.
This development is significant for the psychedelic medicine sector, as it demonstrates the feasibility of cross-border supply chains for controlled substances. Optimi Health is one of the few companies with GMP certification for psychedelic drug production, and this export marks a step toward broader international clinical adoption. The UK trial could provide further evidence on the efficacy of psilocybin for mental health conditions, potentially accelerating regulatory approvals in other jurisdictions.
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, it produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
The successful export to the UK highlights the increasing global interest in psychedelic-based treatments and positions Optimi Health as a key player in the supply chain. For more information, visit Optimi Health or optimi.net. The full press release is available at this link.